Omeros VP Borges sells $750k in shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Omeros Corporation (OMER)
Omeros Corporation stock price live, this page displays NASDAQ OMER stock exchange data. View the OMER premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Omeros Corporation real time stock price chart below.
What Is the Omeros Corporation Stock Price Today?
The Omeros Corporation stock price today is 11.930.
What Is the Stock Symbol for Omeros Corporation?
The stock symbol for Omeros Corporation is "OMER."
What Stock Exchange Does Omeros Corporation Trade On?
Omeros Corporation is listed and trades on the NASDAQ stock exchange.
Is Omeros Corporation a Good Stock to Buy?
Determining whether Omeros Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OMER quote. (ISIN: US6821431029)
What Is the Omeros Corporation Stock Price Today?
The Omeros Corporation stock price today is 11.930.
What Is the Stock Symbol for Omeros Corporation?
The stock symbol for Omeros Corporation is "OMER."
What Stock Exchange Does Omeros Corporation Trade On?
Omeros Corporation is listed and trades on the NASDAQ stock exchange.
Is Omeros Corporation a Good Stock to Buy?
Determining whether Omeros Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OMER quote. (ISIN: US6821431029)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.880
12.215
52 wk Range
2.950
17.650
OMER is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.88012.215
52 wk Range
2.95017.650
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OMER Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
38.000
Upside
+218.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 8K Omeros Corporation For: 29 December
- Investing.com
- Omeros VP Borges sells $750k in shares
- Investing.com
- Form 8K Omeros Corporation For: 29 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Omeros Corporation Company Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation Earnings Call Summary for Q3/2025
- Omeros reported Q3 2025 EPS of -$0.34, beating forecasts of -$0.45, though net loss increased to $30.9M from $25.4M in Q2 2025.
- Stock fell 8.85% in after-hours trading despite the earnings beat, closing at $6.89, reflecting investor concerns about long-term financial health.
- Company expects significant financial strengthening from upcoming Novo Nordisk transaction valued at up to $2.1B, with cash flow positivity projected by 2027.
- Cash position stood at $36.1M as of September 30, with additional $29.3M raised through direct offering and ATM program during the quarter.
- CEO highlighted company's strategic positioning and advancing pipeline, including MASP-2 franchise and preparations for Yartemlya commercial launch pending regulatory approval.
Last Updated: 2025-11-13, 05:42 p/m
Read Full TranscriptCompare OMER to Peers and Sector
Metrics to compare | OMER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMERPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | 6.0x | −0.6x | |
PEG Ratio | −0.61 | 0.02 | 0.00 | |
Price/Book | −3.8x | 2.5x | 2.6x | |
Price / LTM Sales | - | 2.6x | 3.4x | |
Upside (Analyst Target) | 218.5% | 180.4% | 42.0% | |
Fair Value Upside | Unlock | 20.5% | 5.0% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 38.000
(+218.52% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.34 / -0.45
Revenue / Forecast
-- / 312.50K
People Also Watch
FAQ
What Is the Omeros (OMER) Stock Price Today?
The Omeros stock price today is 11.930
What Stock Exchange Does Omeros Trade On?
Omeros is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Omeros?
The stock symbol for Omeros is "OMER."
What Is the Omeros Market Cap?
As of today, Omeros market cap is 845.84M.
What Is Omeros's Earnings Per Share (TTM)?
The Omeros EPS (TTM) is -2.01.
When Is the Next Omeros Earnings Date?
Omeros will release its next earnings report on Mar 03, 2026.
From a Technical Analysis Perspective, Is OMER a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Omeros Stock Split?
Omeros has split 0 times.
How Many Employees Does Omeros Have?
Omeros has 202 employees.
What is the current trading status of Omeros (OMER)?
As of Jan 25, 2026, Omeros (OMER) is trading at a price of 11.930, with a previous close of 12.150. The stock has fluctuated within a day range of 11.880 to 12.215, while its 52-week range spans from 2.950 to 17.650.
What Is Omeros (OMER) Price Target According to Analysts?
The average 12-month price target for Omeros is USD38.000, with a high estimate of USD40 and a low estimate of USD36. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +218.52% Upside potential.
What Is the OMER Premarket Price?
OMER's last pre-market stock price is 12.103. The pre-market share volume is 16,550.000, and the stock has decreased by -0.047, or -0.390%.
What Is the OMER After Hours Price?
OMER's last after hours stock price is 12.080, the stock has decreased by 0.150, or 1.260%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.